IHS Chemical Week

Regions :: North America :: U.S.

Lonza and BioWa sign license agreements with Pfizer

7:30 AM MDT | July 30, 2013 | Deepti Ramesh

Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into research agreements with Pfizer allowing the use of the Potelligent CHOK1SV cell line in the R&D of multiple proprietary antibodies in Pfizer’s pipeline, Lonza says. Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies. The cell line combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS system includes Lonza’s...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa